BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 36611025)

  • 1. Effects of peripheral blood leukocyte count and tumor necrosis factor-alpha on early death in acute promyelocytic leukemia.
    Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
    BMC Cancer; 2023 Jan; 23(1):27. PubMed ID: 36611025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Does leukocytosis remain a predictive factor for survival outcomes in patients with acute promyelocytic leukemia receiving ATRA plus a chemotherapy-based regimen? A prospective multicenter analysis from TALWG.
    Kungwankiattichai S; Owattanapanich W; Rattanathammethee T; Rattarittamrong E; Chanswangphuwana C; Polprasert C; Limvorapitak W; Saengboon S; Niparuck P; Puavilai T; Julamanee J; Saelue P; Wanitpongpun C; Prayongratana K; Sriswasdi C; Nakhakes C
    Hematology; 2023 Dec; 28(1):2191462. PubMed ID: 36951362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia.
    Wang F; Jia JS; Wang J; Zhao T; Jiang Q; Jiang H; Zhu HH
    Leuk Res; 2017 Oct; 61():84-88. PubMed ID: 28934679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia.
    Zhao S; Ge Y; Li Z; Yang T
    Front Immunol; 2023; 14():1100151. PubMed ID: 37063881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
    Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
    Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone.
    Chen X; Fan S; Zhao Y; Zhou J
    Clin Transl Oncol; 2021 Oct; 23(10):2171-2180. PubMed ID: 33942222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
    Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
    Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High body mass index is an independent predictor of differentiation syndrome in patients with acute promyelocytic leukemia.
    Jeddi R; Ghédira H; Mnif S; Gouider E; Fenaux P; Meddeb B
    Leuk Res; 2010 Apr; 34(4):545-7. PubMed ID: 19800119
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Characteristics and Treatment Outcomes of Childhood Acute Promyelocytic Leukemia in Korea: A Nationwide Multicenter Retrospective Study by Korean Pediatric Oncology Study Group.
    Park KM; Yoo KH; Kim SK; Lee JW; Chung NG; Ju HY; Koo HH; Lyu CJ; Han SM; Han JW; Choi JY; Hong KT; Kang HJ; Shin HY; Im HJ; Koh KN; Kim H; Kook H; Baek HJ; Kim BR; Yang EJ; Lim JY; Park ES; Choi EJ; Park SK; Lee JM; Shim YJ; Kim JY; Park JK; Kong SG; Choi YB; Cho B; Lim YT
    Cancer Res Treat; 2022 Jan; 54(1):269-276. PubMed ID: 33887821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics features and factors influencing early death in Acute promyelocytic leukemia; Experience from United Arab Emirates (UAE).
    Hassan IB; Zaabi MRA; Alam A; Hashim MJ; Tallman MS; Kristensen J
    Int J Hematol; 2017 Jul; 106(1):90-98. PubMed ID: 28293819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of initiation time and white blood cell count on the efficacy of cytotoxic agents in acute promyelocytic leukemia during induction treatment.
    Xu F; Yin CX; Wang CL; Ding BJ; Zhong QX; Jiang XJ; Jiang L; Wang ZX; Meng FY
    Biomed Rep; 2018 Sep; 9(3):227-232. PubMed ID: 30271598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia.
    Zhao H; Zhao Y; Zhang Y; Hou J; Yang H; Cao F; Yang Y; Hou W; Sun J; Jin B; Fu J; Li H; Wang P; Ge F; Zhou J
    Ann Hematol; 2018 Mar; 97(3):409-416. PubMed ID: 29289982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of early death and clinical features in newly diagnosed patients with low-intermediate risk acute promyelocytic leukemia.
    Wen J; Xu F; Zhou Q; Shi L; Liu Y; Yue J; Zhang Y; Liang X
    Front Oncol; 2022; 12():895777. PubMed ID: 36185183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival and prognostic study in acute promyelocytic leukemia treated with all-trans-retinoic acid, chemotherapy, and As2O3: an experience of 120 patients at a single institution.
    Hu J; Shen ZX; Sun GL; Chen SJ; Wang ZY; Chen Z
    Int J Hematol; 1999 Dec; 70(4):248-60. PubMed ID: 10643151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group.
    De Botton S; Dombret H; Sanz M; Miguel JS; Caillot D; Zittoun R; Gardembas M; Stamatoulas A; Condé E; Guerci A; Gardin C; Geiser K; Makhoul DC; Reman O; de la Serna J; Lefrere F; Chomienne C; Chastang C; Degos L; Fenaux P
    Blood; 1998 Oct; 92(8):2712-8. PubMed ID: 9763554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interleukin-8 is not a predictive biomarker for the development of the acute promyelocytic leukemia differentiation syndrome.
    Yamamoto de Almeida L; Pereira-Martins DA; Lima ASG; Baggio MS; de Araujo Koury LC; Lange AP; Bassi SC; Scheucher PS; Rego EM
    BMC Cancer; 2020 Aug; 20(1):821. PubMed ID: 32859169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of thrombohemorrhagic early death in children and adolescents with t(15;17)-positive acute promyelocytic leukemia treated with ATRA and chemotherapy.
    Abla O; Ribeiro RC; Testi AM; Montesinos P; Creutzig U; Sung L; Di Giuseppe G; Stephens D; Feusner JH; Powell BL; Hasle H; Kaspers GJL; Dalla-Pozza L; Lassaletta A; Tallman MS; Locatelli F; Reinhardt D; Lo-Coco F; Hitzler J; Sanz MA
    Ann Hematol; 2017 Sep; 96(9):1449-1456. PubMed ID: 28597167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
    Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L
    Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characteristics and predictors of early hospital deaths in newly diagnosed APL: a 13-year population-wide study.
    Gill H; Yung Y; Chu HT; Au WY; Yip PK; Lee E; Yim R; Lee P; Cheuk D; Ha SY; Leung RYY; Ma ESK; Kumana CR; Kwong YL
    Blood Adv; 2021 Jul; 5(14):2829-2838. PubMed ID: 34269798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
    Lou Y; Ma Y; Sun J; Suo S; Tong H; Qian W; Mai W; Meng H; Jin J
    Ann Hematol; 2017 Nov; 96(11):1793-1800. PubMed ID: 28823055
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.